非酒精性脂肪性肝炎的血清学诊断

胡迎; 李良平

doi:10.3969/j.issn.1001-5256.2018.09.037

非酒精性脂肪性肝炎的血清学诊断

DOI: 10.3969/j.issn.1001-5256.2018.09.037

胡迎,
李良平

1. 遵义医学院消化内科
2. 四川省医学科学院四川省人民医院消化内科

基金项目:

四川省卫计委重点课题(16ZD024)；

详细信息

中图分类号: R575
计量
- 文章访问数: 1978
- HTML全文浏览量: 23
- PDF下载量: 432
- 被引次数: 0
出版历程
- 收稿日期: 2018-04-11
- 出版日期: 2018-09-20

Serological noninvasive diagnosis of nonalcoholic steatohepatitis

Department of Gastroenterology, Zunyi Medical College

Research funding:

摘要

摘要: 非酒精性脂肪性肝炎是一种可能导致肝纤维化、肝硬化、肝癌的渐进式疾病,其早期诊断对于延缓疾病进展有重要意义。近年来,越来越多的血清学指标和模型不断被发现,同时基于多项指标的联合应用模型也不断更新,其对脂肪性肝炎和肝纤维化都具有一定的诊断效能。总结并阐述了诊断价值较高的非酒精性脂肪性肝炎、肝纤维化血清学无创诊断的方法。
- 非酒精性脂肪性肝炎 /
- 肝硬化 /
- 诊断 /
- 血清学试验 /
- 综述
Abstract: Nonalcoholic steatohepatitis is a progressive disease that can lead to hepatic fibrosis, liver cirrhosis, and liver cancer, and its early diagnosis is of great significance for delaying disease progression. In recent years, more and more serological markers and models have been found, and the application models based on the combination of various indicators have been updated; these models have a certain diagnostic efficiency for both nonalcoholic steatohepatitis and hepatic fibrosis. This article reviews the research on serological noninvasive diagnosis of nonalcoholic steatohepatitis and hepatic fibrosis.
- non-alcoholic steatohepatitis /
- liver cirrhosis /
- diagnosis /
- serologic tests /
- review

HTML全文

参考文献(23)

[1]CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of non-alcoholic fatty liver disease:Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association[J].Hepatology, 2012, 55 (6) :2005-2023.

[2]REVIEW T, ZAIGHAM A, FRANK A, et al.World Gastroenterology Organisation global guidelines:Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J].J Clin Gastroenterol, 2014, 48 (6) :467-473.

[3]SINGAL A, MANJUNATH H, YOPP AC, et al.The effect of PNPLA3 on fibrosis progression and development of hepato-cellular carcinoma:A meta-analysis[J].Am J Gastroenterol, 2014, 109:325-334.

[4]JIANG LN, ZHAO JM.The role of liver histology in the clinical study and practice of non-alcoholic fatty liver disease[J].J Clin Hepatol, 2017, 33 (12) :2303-2306. (in Chinese) 蒋丽娜, 赵景民.肝组织学评估在非酒精性脂肪性肝病临床研究及实践中的作用[J].临床肝胆病杂志, 2017, 33 (12) :2303-2306.

[5]YOSHIO S, ATSUSHI N, YOSHITO I, et al.Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J].World JGastroenterol, 2014, 20 (2) :475-485.

[6]WATANABE S, HASHIMOTO E, IKEJIMA K, et al.Evidencebased clinical practice guidelines for nonalcoholic fatty liver disease nonalcoholic steatohepatitis[J].J Gastroenterol, 2015, 50 (4) :364-377.

[7]EDUARDO V, NAGA C.Non-invasive assessment of non-alcoholic fatty liver disease:Clinical prediction rules and blood-based biomarkers[J].J Hepatol, 2018, 68 (2) :305-315.

[8]PETTA S, WONG VW, CAMMC, et al.Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD[J].Aliment Pharmacol Ther, 2017, 46 (6) :617-627.

[9]SUMIDA Y, YONEDA M, HYOGO H, et al.Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population[J].BMC Gastroenterol, 2012, 12:2.

[10]Mc PHERSON S, STEWART SF, HENDERSON E, et al.Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease[J].Gut, 2010, 59 (9) :1265-1269.

[11]GIULIO M, JEAN F, ALI C et al, European Association for the Study of the Liver (EASL) ;European Association for the Study of Diabetes (EASD) ;European Association for the Study of Obesity (EASO) .EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease[J].Obes Facts, 2016, 9 (2) :65-90.

[12]JUAN PA, CRISTIAN HR, CAROLINA M, et al.Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the Chilean population[J].Gastroenterol Hepatol, 2017, 40 (6) :388-394.

[13]MANDELIA C, COLLYER E, MANSOOR S, et al.Plasma cytokeratin-18 level as a novel biomarker for liver fibrosis in children with nonalcoholic fatty liver disease[J].J Pediatr Gastroenterol Nutr, 2016, 63 (2) :167-168.

[14]CUSI K, CHANG Z, HARRISON S, et al.Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease[J].J Hepatol, 2014, 60 (1) :167-174.

[15]BI Y, MIN M, SHEN W, et al.Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease[J].Int J Clin Exp Pathol, 2015, 8 (7) :8494-8499.

[16]YONEDA M, MAWATARI H, FUJITA K, et al.High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH[J].J Gastroenterol, 2007, 42 (7) :573-582.

[17]MALEKI I, RASTGAR A, HOSSEINI V, et al.High sensitive CRP and pentraxine 3 as noninvasive biomarkers of nonalcoholic fatty liver disease[J].Eur Rev Med Pharmacol Sci, 2014, 18 (11) :1583-1590.

[18]LEE J, YOON K, RYU S, et al.High-normal levels of hs-CRPpredict the development of non-alcoholic fatty liver in healthy men[J].PLo S One, 2017, 12 (2) :e0172666.

[19]MIELE L, de MICHELE T, MARRONE G, et al.Enhanced liver fibrosis test as a reliable tool for assessing fibrosis in nonalcoholic fatty liver disease in a clinical setting[J].Int J Biol Markers, 2017, 32 (4) :e397-e402.

[20]YOSHIO S, MASATO Y, HIDEYUKI H, et al.A simple clinical scoring system using ferritin, fasting insulin, and typeⅣcollagen 7Sfor predicting steatohepatitis in nonalcoholic fatty liver disease[J].J Gastroenterol, 2011, 46 (2) :257-268.

[21]TADA T, KUMADA T, TOYODA H, et al.New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease[J].Biomarkers, 2018, 23 (4) :328-334.

[22]TAKESHI O, HAYAO E, TOSHIHIRO K, et al.A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis[J].JGastroenterol, 2018, 53 (1) :129-139.

[23]YOSHIHIRO K, MASAFUMI O, HIDEYUKI H, et al.A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers[J].Hepatology, 2015, 62 (5) :1433-1443.

施引文献

资源附件(0)

访问统计